Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Equity (2016 - 2025)

Neurocrine Biosciences' Return on Equity history spans 15 years, with the latest figure at 0.15% for Q4 2025.

  • For Q4 2025, Return on Equity rose 2.0% year-over-year to 0.15%; the TTM value through Dec 2025 reached 0.15%, up 2.0%, while the annual FY2025 figure was 0.16%, 2.0% up from the prior year.
  • Return on Equity reached 0.15% in Q4 2025 per NBIX's latest filing, up from 0.15% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.34% in Q1 2021 to a low of 0.01% in Q2 2022.
  • Average Return on Equity over 5 years is 0.14%, with a median of 0.12% recorded in 2024.
  • The largest YoY upside for Return on Equity was 22bps in 2021 against a maximum downside of -36bps in 2021.
  • A 5-year view of Return on Equity shows it stood at 0.07% in 2021, then soared by 44bps to 0.1% in 2022, then grew by 24bps to 0.12% in 2023, then increased by 9bps to 0.13% in 2024, then rose by 19bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Return on Equity are 0.15% (Q4 2025), 0.15% (Q3 2025), and 0.13% (Q2 2025).